Rova-T Program Ended in Small Cell Lung Cancer - OncLive

Rova-T Program Ended in Small Cell Lung Cancer  OncLive

AbbVie has officially ended its rovalpituzumab tesirine (Rova-T) research and development program, which was exploring the antibody-drug conjugate in ...



Comments

Popular posts from this blog